Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ZBIO

ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) Price, Holdings, & News

ProShares UltraPro Short Nasdaq Biotechnology logo

About ProShares UltraPro Short Nasdaq Biotechnology (NASDAQ:ZBIO)

Advanced Chart

Key Stats

Today's Range
$7.49
$8.30
50-Day Range
$10.02
$10.09
52-Week Range
$8.28
$18.64
Volume
172,236 shs
Average Volume
198,410 shs
Market Capitalization
$327.22 million
Assets Under Management
$2.85 million
Dividend Yield
N/A
Net Expense Ratio
0.95%
Aggregate Rating
N/A

ETF Overview

Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc?RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass.

ProShares UltraPro Short Nasdaq Biotechnology Expenses

TypeZBIOHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.75%0.57%0.56%0.51%0.53%
Other Expenses1.02%0.30%0.50%0.47%0.53%
Total Expense1.77%0.70%0.72%0.67%0.71%
Fee Waiver-0.82%-0.45%-0.50%-0.32%-0.56%
Net Expense0.95%0.61%0.62%0.60%0.60%
Receive ZBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProShares UltraPro Short Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

ZBIO ETF News Headlines

DOGE To DO List
Elon's found so much waste he's now claiming "the magnitude of the fraud in federal entitlements" is greater than "the combined sum of every private scam you've ever heard by FAR"... And while this is disturbing and even infuriating to see our tax money literally wasted... there IS a solution. I believe it's Elon's ultimate end game.
See More Headlines

ZBIO ETF - Frequently Asked Questions

ProShares UltraPro Short Nasdaq Biotechnology (NASDAQ:ZBIO) released its earnings results on Tuesday, November, 12th. The company reported ($5.02) earnings per share for the quarter, beating analysts' consensus estimates of ($13.00) by $7.98.

ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) raised $225 million in an IPO on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share.

ProShares UltraPro Short Nasdaq Biotechnology's lock-up period expires on Wednesday, March 12th. ProShares UltraPro Short Nasdaq Biotechnology had issued 13,235,294 shares in its initial public offering on September 13th. The total size of the offering was $224,999,998 based on an initial share price of $17.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares UltraPro Short Nasdaq Biotechnology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Fund Details

Issuer
ProShares
Fund Name
ProShares UltraPro Short Nasdaq Biotechnology
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:ZBIO
Inception Date
6/22/2015
Fund Manager
Michael Neches, Tarak Dave

Fund Focus

Asset Class
Equity
Benchmark
NASDAQ Biotechnology Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
0

Fund Statistics

Assets Under Management
$2.85 million
Average Daily Volume
$25,501.70
Discount/Premium
0.00%

Administrator, Advisor and Custodian

Administrator
J.P. Morgan Investor Services Co.
Advisor
ProShare Advisors LLC
Custodian
JPMorgan Chase Bank, N.A.
Distributor
SEI Investments Distribution Co.
Transfer Agent
JPMorgan Chase Bank, N.A.
Trustee
N/A
Lead Market Maker
Virtu Financial

Miscellaneous

Beta
N/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ZBIO) was last updated on 2/24/2025 by MarketBeat.com Staff
From Our Partners